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Background
Long-term immune recovery in older patients given hematopoietic cell transplantation after
non-myeloablative conditioning remains poorly understood. This prompted us to investigate
long-term lymphocyte reconstitution and thymic function in 80 patients given allogeneic
peripheral blood stem cells after non-myeloablative conditioning.
Design and Methods
Median age at transplant was 57 years (range 10-71). Conditioning regimen consisted of 2 Gy
total body irradiation (TBI) with (n=46) or without (n=20) added fludarabine, 4 Gy TBI with
fludarabine (n=6), or cyclophosphamide plus fludarabine (n=8). Stem cell sources were unma-
nipulated (n=56), CD8-depleted (n=19), or CD34-selected (n=5) peripheral blood stem cells.
Immune recovery was assessed by signal-joint T-cell receptor excision circle quantification and
flow cytometry. 
Results
Signal-joint T-cell receptor excision circle levels increased from day 100 to one and two years
after transplantation in patients under 50 years of age (n=23; P=0.02 and P=0.04, respectively),
and in those aged 51-60 years (n=35; P=0.17 and P=0.06, respectively), but not in patients aged
over 60 (n=22; P=0.3 and P=0.3, respectively). Similarly, CD4+CD45RA+ (naïve) T-cell counts
increased from day 100  to one and two years after transplantation in patients aged 50 years
and under 50 (P=0.002 and P=0.02, respectively), and  in those aged 51-60 (P=0.4 and P=0.001,
respectively), but less so in patients aged over 60 (P=0.3 and P=0.06, respectively). In multivari-
ate analyses, older patient age (P<0.001), extensive chronic GVHD (P<0.001), and prior
(resolved) extensive chronic graft-versus-host disease (P=0.008) were associated with low sig-
nal-joint T-cell receptor excision circle levels one year or more after HCT.  
Conclusions
In summary, our data suggest that thymic neo-generation of T cells occurred from day 100
onwards in patients under 60 while signal-joint T-cell receptor excision circle levels remained
low for patients aged over 60. Further, chronic graft-versus-host disease had a dramatic impact
on thymic function, as observed previously in patients given grafts after myeloablative condi-
tioning.
Key words: thymus, hematopoietic cell transplantation, non-myeloablative, graft-versus-host
disease, immunity, age.
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Introduction
It is well established that the thymus undergoes a phys-
iological involution with aging that affects its structure
and cytokine environment.1,2 However, studies by
Steinman et al. in the 1980s documented lymphocytic
thymic tissue in adults up to 107 years of age.1 Further,
several studies have suggested that the human thymus
could continue to mature new T cells throughout life,
exporting signal-joint T-cell receptor excision circle
(sjTREC) bearing T cells into the peripheral blood even in
elderly patients.3-5
Non-myeloablative conditioning regimens followed by
allogeneic hematopoietic cell transplantation (HCT) have
opened the way to performing allogeneic HCT in patients
with hematologic malignancies aged up to 70-75 years.6-9
This approach has relied on optimization of pre- and post-
transplant immunosuppression to overcome graft-versus-
host disease (GVHD) reactions,10 thereby allowing
engraftment and eradication of tumors nearly exclusively
via immune-mediated graft-versus-tumor effects.11-13
T-cell recovery after allogeneic HCT following high-
dose (myeloablative) conditioning depends on both
peripheral expansion of mature T cells contained in the
graft (thymo-independent pathway), and T-cell neo-pro-
duction from donor hematopoietic stem cells (thymo-
dependent pathway).14-17 In young patients given myeloab-
lative allogeneic HCT, most circulating T cells during the
first 3-6 months following HCT are the progeny of T cells
infused with the grafts,18 while neogeneration of T cells by
the thymus plays an important role in reconstituting the T-
cell pool beyond day 100 after HCT.19-24
We recently analyzed immune recovery after non-mye-
loablative conditioning the first year after non-myeloabla-
tive conditioning.25,26 Main observations were that unrelat-
ed donor status and donor age affected early immune
recovery,25 while sjTREC levels significantly increased
from day 100 to day 365 in a cohort of 16 patients,26 sug-
gesting that the thymic pathway might play a role in
immune recovery in these older patients given non-mye-
loablative conditioning. Here, we analyzed long-term (one
year or more) immune recovery and thymic function in 80
patients given non-myeloablative conditioning regimen. 
Design and Methods
Patients and donors
Data from 80 patients transplanted between March 2000 and
April 2008 at the University of Liège were included in the study.
Results were analyzed as of July 29, 2009. Patients’ characteristics
are summarized in the Online Supplementary Table S1. Median
patient age was 57 (range 10-71) years. Thirty-three of the 80
patients received grafts from HLA-matched related donors, 22
from HLA-matched unrelated donors, and 25 from HLA-mis-
matched related or unrelated donors. Stem cell sources were
unmanipulated (n=56), CD8-depleted (n=19), or CD34-selected
(n=5) peripheral blood stem cells (PBSC). CD8-depletion and
CD34-selection of PBSC were carried out as previously report-
ed.26,27 Nine patients given grafts from HLA-mismatched donors
were enrolled in a trial of mesenchymal stem cell co-transplanta-
tion as a potential way to prevent severe GVHD28. Immune recov-
ery in 35 of the 80 patients for the first six (n=14)27 or 12 (n=21)26
months after HCT has been reported previously. Written informed
consent was obtained from each patient to undergo non-myeloab-
lative HCT and to collect, store and analyze blood samples for
research purposes. The Ethics Committee of the University of
Liège approved the consent form as well as the current research
study protocol.
Treatment and evaluation
The non-myeloablative conditioning regimens consisted of 2
Gy total body irradiation (TBI) alone (n=20; patients with low risk
of graft rejection given PBSC from HLA-identical siblings), 2 Gy
TBI with 90 mg/m2 fludarabine (n=46; standard regimen), 4 Gy
TBI with 90 mg/m2 fludarabine (n=6; patients at high risk of early
disease progression and/or graft rejection), or fludarabine 90
mg/m2 with cyclophosphamide 3 g/m2 (n=8, patients with previ-
ous irradiation precluding the use of TBI). Post-grafting immuno-
suppression combined mycophenolate mofetil (MMF) with a cal-
cineurin inhibitor for all patients, as previously described.26,27
Clinical management
Twenty-four patients received at least one unmanipulated
(n=18) or CD8-depleted (n=6) pre-emptive donor lymphocyte
infusion (DLI) the first year after HCT (including the 5 patients
given CD34-selected PBSC who received CD8-depleted pre-
emptive DLI). G-CSF (5 μg/kg/d) was administered when the
granulocyte count declined below 1.0¥109/L. The diagnosis, clin-
ical grading, and treatment of acute GVHD were performed
according to established criteria.29 Treatment was usually given
for grade II-IV acute GVHD and for extensive chronic GVHD.
Initial treatment of acute GVHD usually consisted of pred-
nisolone, 2 mg/kg/day, with tapering initiated within 14 days. In
addition, the calcineurin inhibitor was usually resumed at full
doses. Steroid-refractory acute GVHD was treated as per avail-
able investigational protocols or standard practice. Treatment of
chronic GVHD consisted of methylprednisolone (1 mg/kg) with
alternate-day calcineurin inhibitor. Steroid-refractory chronic
GVHD was generally treated with rapamycin, mycophenolate
mofetil, or photophoresis. 
Infection prophylaxis generally consisted of acyclovir (400 mg
t.i.d. orally), oral itraconazole solution (200 mg b.i.d.) or oral flu-
conazole (200 mg b.i.d.), and trimethoprim sulfamethoxazole or
aerosolized pentamidine. Polymerase chain reaction (PCR) for
cytomegalovirus (CMV) was performed weekly until day 100
and every 2-4 weeks thereafter. Patients with a positive PCR
received preemptive i.v. ganciclovir.
Disease evaluations were routinely carried out on days 40, 100,
180 and 365 after HCT. 
Chimerism 
Chimerism levels among peripheral T cells were assessed on
days 28, 40, 100, 180 and 365 after HCT using fluorescence in situ
hybridization to detect X and Y chromosomes for recipients of
sex-mismatched transplants and PCR-based analysis of polymor-
phic microsatellite regions (AmpFlSTR® Identifiler®, Applied
Biosystems, Lennik, Belgium) for recipients of sex-matched trans-
plants.26,27 CD3 (T cell) selection was carried out with the
RosetteSepR human T-cell enrichment kit (StemCell Technologies,
Vancouver, Canada). Graft rejection was defined as the occurrence
of less than 5% T cells of donor origin after HCT, as previously
described.30,31
Immune recovery
Immune recovery was prospectively assessed as previously
described.27 Briefly, patients’ peripheral white blood cells were
phenotyped on days 28, 42, 60, 80, 100, 120, 180, 365, 540, 730
and yearly thereafter using 4 color flow cytometry after treatment
with a red blood cell lyzing solution. The analyzed cell subsets
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were T cells (CD3+), CD4+ T cells (CD3+CD4+ lymphocytes), CD8+
T cells (CD3+CD8+ lymphocytes), naïve CD4+ T cells
(CD4+CD45RAhigh double positive lymphocytes), memory CD4+ T
cells (CD4+CD45RO+ double positive lymphocytes), NK cells
(CD3-CD56+ lymphocytes) as well as B cells (CD19+ lympho-
cytes). The percentage of positive cells was measured relative to
total nucleated cells, after subtraction of non-specific staining.
Absolute counts were obtained by multiplying the percentages of
positive cells by the white blood cell counts (Advia 120 hematol-
ogy analyzer, Bayer Technicon, Tarrytown, USA). Lower and
higher limits of normal values for each cell subset were defined
respectively as 5 and 95 percentiles of values obtained in 47 age-
matched healthy volunteer donors.
More detailed T- and B-cell phenotyping was retrospectively
performed using cryopreserved PBMC from 33 patients obtained
two years after transplantation using 6 color flow cytometry. The
different populations were defined as follows: naïve CD4+ T cells,
CD4+CD45RA+CCR7+CD27+ lymphocytes; central memory CD4+
T cells, CD4+CD45RA-CCR7+CD27+ lymphocytes; effector mem-
ory CD4+ T cells, CD4+CD45RA-CCR7-CD27+ lymphocytes; late
differentiation effector memory CD4+ T cells, CD4+CD45RA-
CCR7-CD27- lymphocytes; naïve CD8+ T cells,
CD8+CD45RA+CCR7+ lymphocytes; central memory CD8+ T
cells, CD8+CD45RA-CCR7+ lymphocytes; effector memory CD8+
T cells, CD8+CD45RA-CCR7- lymphocytes; effector memory RA+
CD8+ T cells, CD8+CD45RA+CCR7- lymphocytes; naïve B cells,
CD19+CD27- lymphocytes; memory B cells, CD19+CD27+ lym-
phocytes; IgM+IgD+ memory B cells, CD19+CD27+IgM+IgD+ lym-
phocytes; switched memory B cells, CD19+CD27+IgM-IgD- lym-
phocytes. Absolute counts were calculated by multiplying the per-
centage of positive cells in the lymphoid gate by the absolute lym-
phocyte count of the patient the day of PBMC collection. 
CDR3 spectratyping (immunoscope)
T-cell receptor beta chain (TCRB) CDR3 spectratyping analyses
were performed between two  and nine (median three) years after
HCT in 21 patients. RNA was extracted from 10¥106 cells by
Tripure (Roche) according to the manufacturer’s protocol. The
quality of the extracted RNA was controlled using the Experion
RNA StdSens Starter Kit (Bio-Rad, Nazareth Eke, Belgium) in a gel
electrophoresis experiment (Experion Automated Electrophoresis
System, Bio-Rad). RNA optical density measurements were per-
formed on a Nanodrop ND1000 (Isogen, Sint-Pieters Leeuw,
Belgium). First-strand cDNA was generated from 1 μg total RNA
using Transcriptor 1st strand cDNA synthesis kit (Roche) according
to the manufacturer’s protocol. Each TCRB segment was ampli-
fied with one of the 24 TCRBV family-specific primers (Vb1-
Vb24) and a TCRBC primer conjugated to fluorescent dye 6-FAM
(Applied Biosystems, Lennik, Belgium) for CDR3 analysis. The
size distribution of each fluorescent PCR product was determined
by electrophoresis on an ABI 3730 automatic capillary sequencer
(Applied Biosystems, Foster City, CA, USA) and data were ana-
lyzed by Genemapper v4.0 (Perkin Elmer Cetus Instruments,
Emeryville, CA, USA). The overall complexity within a T-cell
receptor Vbeta subfamily was determined by counting the num-
ber of peaks (intervals of 3 nucleotides) per subfamily. The overall
spectratyping complexity (T-cell receptor Vbeta score) was calcu-
lated as the sum of the numbers of peaks in the 24 subfamilies.
The median T-cell receptor Vbeta score in 20 age-matched volun-
teer blood donors was 239 (range 179-251) peaks. Further, in order
to measure the deviation from normality of a repertoire, we meas-
ured its quadratic distance to the average of 2 normalized reper-
toires that were each artificially created by mixing in comparable
amounts the cDNAs of the PBMC of 6 age-matched volunteer
blood donors, as previously reported.32
T-cell receptor excision circles (TREC) assay
Blood samples were collected on days 40, 100, 180, 365, 540
and then yearly after HCT. TREC assays were performed on
samples collected on days 100, 365, 540 and then yearly after
HCT as previously described. Briefly, peripheral blood mononu-
clear cells (PBMC) were isolated using Ficoll-Hypaque
(Amersham Pharmacia Biotech, Uppsala, Sweden) gradient cen-
trifugation and then cryopreserved. SjTREC were quantified for
each sample by nested real time PCR, as previously
described.26,33 Briefly, thawed PBMC were lysed 30 min at 56°C
with Tween-20 (0.05%), NP-40 (0.05%) and Proteinase K (100
μg/mL). Cell lysis was stopped by incubating 15 min at 99°C.
Multiplex PCR amplification was achieved for sjTREC together
with the CD3gamma/chain, used as a housekeeping gene, with
specific 3’/5’ outer primers for each amplicon. Cycle conditions
and primer/probe sequences have been reported elsewhere.33-35
PCR products were 10-fold diluted prior to PCR quantification
using the Lightcycler™ technology. Quantitative PCR conditions
were: 5 min initial denaturation at 95°C followed by 40 cycles of
amplification (5 second at 95°C, 15 seconds at 60°C, 10 seconds
at 72°C). Fluorescence emissions were assessed after the
hybridization steps. Each PCR product was run for both sjTREC
and CD3/gamma chain in 2 separate Lightcycler experiments.
Every sample was run in at least 2 independent experiments.
The results were first calculated as absolute numbers of sjTREC
per 105 PBMC; because each PBMC contains 2 CD3/gamma
chain copies, sjTREC/105 PBMC=(sjTREC/CD3gamma) x 2 105.
Because sjTREC are only present in lymphocytes, and because
PBMC composition can be variable, sjTREC concentration in
peripheral blood was computed using the formula: (sjTREC/105
PBMC x PBMC/μL) /100 where PBMC/μL=(white blood cells
/μL x (%lympho + %mono))/100. Similar adjustments for calcu-
lating absolute T-cell subset counts from their frequencies in
PBMC have been made previously by other groups of investiga-
tors.36 The nested character of this quantitative PCR allows high
sensitivity (detection of one copy of sjTREC per PCR reaction).
SjTRECs were also measured in 47 age-matched healthy volun-
teers.
Statistical analyses
Wilcoxon’s matched pair test was used to compare sjTRECs
concentrations and CD4+CD45RA+ T cells at day 100 after HCT
with values obtained in the same patients on days 365 and 730
after HCT. Spearman’s correlation coefficient was used to analyze
potential associations between lymphocyte subset counts and
sjTRECs levels after HCT. The Mann-Whitney test was used to
compare lymphocyte subset counts after HCT in patients under
57 years of age or 57  years and over at HCT. To determine factors
affecting the counts of CD3+ T cells, CD4+ T cells, CD4+CD45RA+
(naïve) T cells, CD8+ T cells, B cells, and sjTREC levels at one year
or more after HCT, multivariable linear regression models for the
different MNC counts one year or more year after HCT were fit-
ted using stepwise selection. Potential factors examined were:
patient age, donor age, donor type (related vs. unrelated), HLA-
compatibility (10/10 HLA-matched vs. other), number of CD3+ T
cells transplanted, day post-HCT, extensive chronic GVHD at the
time of analysis, limited chronic GVHD at the time of analysis,
and prior (resolved, defined as discontinuation of systemic
immunosuppressive therapy) extensive chronic GVHD.
Logarithmic transformation of the responses was used for all mod-
els. Patients were censored at the time of graft rejection and/or dis-
ease progression. The comparison of the probability of chronic
GVHD in patients with day 100 sjTREC levels above or below the
median was made with the log rank test. The probability of infec-
tion from one to two years after HCT according to one year
E. Castermans et al.
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sjTREC levels was calculated using the cumulative incidence
method, using death, and graft rejection and progression as com-
petitive risks. Cox’s regression models were applied to fit risk of
dying from infection. Results were significant at the 5% critical
level (P<0.05). Statistical analyses were carried out with Graphpad
Prism (Graphpad Software, San Diego, CA, USA) and SAS version
9.1 for Windows (SAS Institute, Cary, NC, USA).
Results
Reconstitution of thymic function (sjTRECs)
Confirming previous observations by our group in a
cohort of 16 patients,26 thymic function assessed by
sjTREC/mL of blood increased from day 100 to one and
two years after transplantation. Specifically, sjTREC con-
centrations were 786±1,207 sjTREC/mL on day 100,
1,890±4,784 sjTREC/mL one year after HCT (P=0.0066 in
comparison to day 100), and 4,333±1,1131 sjTREC/mL
two years after HCT (P=0.0015 in comparison to day 100
and P=0.0422 in comparison to one year after HCT),
respectively. However, as shown in Figure 1A-D, thymic
recovery did not occur in patients over 60 years of age.
Specifically, sjTREC concentrations increased from day
100 to one and two years after transplantation in patients
aged 50 years and under (P=0.0245 and P=0.0371, respec-
tively), and in those 51-60 years of age (P=0.17 and
P=0.064, respectively), but not in patients over 60 years
old (P=0.3 and P=0.3, respectively), even censored at onset
of chronic GVHD. Similar results were observed when
taking into consideration only patients for whom we had
data on each day 100, one year, two years and three years
after transplantation (Online Supplementary Figure 1A).
An inverse correlation was observed between sjTREC
concentrations one year or more after HCT and recipient
(R=-0.41, P<0.0001) and donor (R=-0.25, P=0.0002) ages
(Figure 2A). In addition, chronic GVHD had a profound
negative impact on sjTREC concentrations one year or
more year after HCT. Specifically, sjTREC concentrations
were 5,018±9,331 sjTREC/mL in patients without chronic
GVHD, 2,493±7,383 sjTREC/mL (P=0.0078) in patients
with limited chronic GVHD, 1,209±5,029 sjTREC/mL
(P<0.0001) in patients with extensive chronic GVHD, and
4,166±12,436 sjTREC/mL (P=0.0021) in patients with
resolved extensive chronic GVHD, respectively. The same
results were observed when the impact of chronic GVHD
presence / severity was assessed separately one year, two
years and three years after transplantation (Figure 2B). As
shown in the Online Supplementary Figure 1C-E, sjTREC
concentrations one year after transplantation were not sta-
tistically affected by PBSC manipulation, donor lympho-
cyte infusion, or by the type of the non-myeloablative
conditioning regimen administered. Further, mean±SD
sjTREC concentration one year after HCT were
2,396±5,963 sjTREC/mL in patients given unmanipulated
PBSC and no MSC, versus 1,303±2,860 sjTREC/mL (P=0.5)
in those given unmanipulated PBSC and MSC.  
We then performed a multivariate analysis of factors
affecting long-term thymic function, taking together
sjTREC data from each patient at any time point one year
or more after HCT (Table 1). In multivariate analysis, high
patient age (P<0.0001), extensive chronic GVHD
(P<0.0001), and resolved extensive chronic GVHD
(P=0.0075) were independently associated with low
sjTREC concentrations (Table 1).
Reconstitution of peripheral lymphocyte subsets
T cells
CD4+ T-cell counts remained below normal values dur-
ing the first 540 days after HCT, then reached the 5th per-
centile of normal values on day 540 after HCT. This was
mainly due to recovery of memory CD4+ T cells that
reached the 5th percentile of normal values on day 365
after HCT, while CD4+CD45RA+ (naïve) T cells remained
below normal values for the first three years after HCT
(Figure 3). Recovery of lymphocyte subset counts were
similar in patients under 57 years of age or 57 years and
over, except for CD4+CD45RA+ (naïve) T-cell recovery
that was lower in older than in younger recipients.
Specifically, CD4+CD45RA+ T-cell counts increased from
day 100 to one and two years after transplantation in
patients aged 50 years and under (P=0.002 and P=0.02,
respectively), and in those 51-60 years of age (P=0.4 and
P=0.001, respectively), but less so in patients over 60
years old (P=0.3 and P=0.06, respectively), even when
censored at onset of chronic GVHD (Figure 1E-H). Similar
results were observed when taking into consideration
only patients for whom we had data on each day 100,
one year, two years and three years after transplantation
(Online Supplementary Figure 1B).
As reported by other investigators,37 we observed a
close correlation between sjTREC concentrations and
CD4+CD45RA+ T-cell counts (R=0.47, P<0.0001) one year
or more after HCT. In contrast to that observed in the
CD4+ T-cell compartment, CD8+ T cells normalized
quickly, reaching the 5th percentile of normal values as
soon as two months after HCT. This indicates that
peripheral expansion of mature T cells contained in the
graft was more efficient for CD8+ T cells than for CD4+ T
cells, as previously reported by other groups of investiga-
tors.15 As shown in the Online Supplementary Figure 1C-E,
CD3+ T cell and CD4+CD45RA+ T-cell counts one year
after transplantation were not statistically affected by
PBSC manipulation, donor lymphocyte infusion, or by
the type of the non-myeloablative conditioning regimen
administered. Furthermore, mean ± SD CD3+ T-cell
counts one year after HCT were 1,350±1,409 cells/μL in
patients given unmanipulated PBSC and no MSC versus
1,867±1,544 cells/μL (P=0.3) in those given unmanipulat-
ed PBSC and MSC.  
B and NK cells
CD19+ B-cell counts reached normal values at one year
after HCT, while the counts of NK cells reached normal
values around six months after HCT.
Multivariate analysis
We then performed a multivariate analysis of factors
affecting long term T- and B-cell immune recovery, taking
together data from each patient at any time point one year
or more after HCT (Table 1). Extensive chronic GVHD was
associated with lower counts of T cells (P<0.001), CD8+ T
cells (P<0.001), CD4+ T cells (P<0.001), CD4+CD45RA+ T
cells (P<0.001), and B cells (P=0.003); higher patient age
was associated with lower counts of CD4+CD45RA+ T
cells (P<0.001) and B cells (P=0.002) while longer delay
after transplantation was associated with higher counts of
CD4+ T cells (P<0.001), CD4+CD45RA+ T cells (P=0.016),
and B cells (P<0.001). Further, patients given grafts contain-
ing less than 1¥106 T cells/kg had lower CD8+ T-cell
(P=0.002) counts.
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Correlation between thymic function and T- and B-cell
phenotypes two years after HCT
We then analyzed the correlation between sjTREC lev-
els two years after HCT and detailed T- and B-cell pheno-
types two years after HCT in a cohort of 33 patients for
whom we had cryopreserved PBMC at that time point.
There was a statistically significant correlation between 2-
year sjTREC levels and patient age (inverse correlation,
R=-0.54, P=0.001) as well as with 2-year counts of naïve
CD4+CD45RA+CCR7+ T cells (positive correlation,
R=0.43, P=0.012), central memory CD4+ T cells (positive
correlation, R=0.38, P=0.028), naïve CD8+ T cells (positive
correlation, R=0.59, P<0.001), central memory CD8+ T
cells (positive correlation, R=0.55, P=0.001), effector mem-
ory CD8+ T cells (positive correlation, R=0.39, P=0.025),
naïve B cells (positive correlation, R=0.53, P=0.001), mem-
ory B cells (positive correlation, R=0.45, P=0.008),
IgM+IgD+ memory B cells (positive correlation, R=0.43,
P=0.012) and switched memory B cells (positive correla-
tion, R=0.45, P=0.008) (Figure 4A-C).
We also analyzed the impact of patient age and exten-
sive chronic GVHD on T- and B-cell phenotypes. Patients
aged 57 years and over (n=15) had lower counts of naïve
CD8+ T cells (P=0.06), naïve B cells (P=0.02), memory B
cells (P=0.06) and switched memory B cells (P=0.006) than
those under 57 years of age at HCT (n=18) (Figure 4D-F).
Finally, patients who had extensive chronic GVHD two
years after HCT had lower counts of effector memory
CD8+ T cells (P=0.04), effector memory RA+ CD8+ T cells
(P=0.04), naïve B cells (P=0.002), memory B cells (P=0.04),
and switched memory B cells (P=0.07) than those who did
not (Figure 4G-I).
Correlation between thymic function and T-cell Vbeta
repertoire diversity
In order to assess the impact of thymic function on
Vbeta repertoire diversity, T-cell receptor Vbeta repertoire
CDR3 spectratyping analyses were performed between
two and nine (median three) years after HCT in 21
patients with low (<500 sjTREC/mL; n=9) or high (>500
sjTREC/mL; n=12) sjTREC levels, measured on the same
day as the spectratyping analysis. As illustrated in the
Online Supplementary Figure 2, the Vbeta repertoire was rel-
atively complex even in patients with low thymic func-
tion, probably reflecting the fact that peripheral expansion
of T cells contained in the graft eventually allowed a rela-
tively diverse T-cell receptor Vbeta  repertoire, although
some oligoclonal T-cell receptor Vbeta families were
observed, and particularly so in patients with low sjTREC
levels. Specifically, median T-cell receptor Vbeta score was
239 (range 179-251) peaks in age-matched controls, 207
E. Castermans et al.
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Table 1. Multivariable analyses of factors affecting immune recovery
one year or more after non-myeloablative conditioning (n=242)*.
Cell subset Factor(s) associated with lower levels / 
cell subset counts
sjTREC concentration - high patient age† (P<0.0001).
- extensive chronic GVHD (P<0.0001).
- antecedent of extensive chronic GVHD 
(P=0.0075).
n. T cells - extensive chronic GVHD (P<0.0001).
- related donor (P=0.0353).
n. CD4+ T cells - extensive chronic GVHD (P=0.0007).
- shorter delay after HCT† (P<0.0001).
n. naïve CD4+ T cells - extensive chronic GVHD (P<0.0001).
- high patient age† (P=0.0004).
- shorter delay after HCT † (P=0.016).
n. CD8+ T cells - extensive chronic GVHD (P=0.0001).
- n. CD3+ T cells transplanted < 1¥106/kg
(P=0.0018).
- absence of limited chronic GVHD (P=0.008).
n. B cells - extensive chronic GVHD (P=0.003).
- high patient age† (P=0.0017).
- shorter delay after HCT† (P=0.0006).
*Other factors assessed were donor age, HLA-mismatch between donor and recipient
or not; †modeled as a continuous linear variable; GVHD, graft-versus-host disease.
Figure 1. Impact of patient age (at HCT) on sjTREC (A-D) and naïve CD4 T cell (E-H) recovery. (D and H) Patients were censured at time of
occurrence of chronic GVHD. P values are given for comparison with day 100 values. 
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(range 173-246) peaks in patients with low sjTREC levels
(P=0.038 in comparison to controls), and 218 (range 182-
252) in patients with high sjTREC levels (NS in compari-
son to controls and to patients with low sjTREC).
Furthermore, we quantified the deviation from normality
of each repertoire by measuring its quadratic distance to
an average repertoire measured in healthy donors (see
Design and Methods section).32 The quadratic distance was
4.5 (range 3.2-6.5) in age-matched controls, 8.1 (range 3.8-
11.3) in patients with low sjTREC levels (P=0.003 in com-
parison to controls), and 5.3 (range 4.5-9.1) in patients
with high sjTREC levels (P=0.016 in comparison to con-
trols, P=0.22 in comparison to patients with low sjTREC).  
Correlation between thymic function and clinical
events
Day 100 sjTREC levels were similar in patients who had
grade II-IV acute GVHD before day 100, as compared to
those who did not (687±947 vs. 824±1,303 sjTREC/mL,
P=0.5). Day 100 sjTREC levels was not associated with
the occurrence of chronic GVHD: the 1-year probability of
chronic GVHD was 57% in patients with day 100 sjTREC
levels below the median (323 sjTREC/mL) versus 52% in
those with higher sjTREC levels on day 100 (P=0.5).
We then studied infections occurring between day 365
to 730 based on day 365 sjTREC levels. The probabilities
of bacterial, fungal and viral infections were 40%, 9%, and
13%, respectively, in patients with day 365 sjTREC levels
below the median (523 sjTREC/mL) versus 31% (P=0.3),
5% (P=0.6) and 17% (P=0.6), respectively, in those with
higher levels. The 7-year probability of dying from infec-
tion was 40% in patients with day 365 sjTREC levels
below the median versus 0% in those with higher values
(P=0.01, Figure 2C). However, 6 of 7 patients who died
from infections had extensive chronic GVHD at the time
of death. Further, the association between 1-year sjTREC
levels and the subsequent risk of dying from infection was
no longer statistically significant (P=0.17) after adjustment
for the presence of extensive chronic GVHD one year after
HCT in a Cox’s model where sjTREC levels were modeled
as a continuous linear variable.
Discussion
Late infections (with or without chronic GVHD) are the
first causes of non-relapse death beyond one year after
HCT in young patients given myeloablative condition-
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Figure 2. (A) Correlation between patient age at HCT and sjTREC levels one year or more after HCT. (B) Impact of chronic GVHD on sjTREC
concentration (mean ± standard deviation) 1-3 years after HCT. Black bars, no chronic GVHD; white bars; limited chronic GVHD, black and
white bars, extensive chronic GVHD; gray bars, resolved extensive chronic GVHD. P values (obtained with the Mann-Whitney test) are given
in comparison to patients without chronic GVHD. (C) Cumulative incidence of dying from infection in patients with sjTREC levels on day 365
below (continuous line) or above (broken line) the median.
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ing.38,39 They have been attributed to slow recovery of
CD4+ T cells.38,40 Nevertheless, despite the well established
association between higher patient age and impaired
immune recovery following allogeneic HCT,14 HCT after
non-myeloablative conditioning has been successful treat-
ment for many patients aged up to between 60 and 70
years of age, most of whom were without evidence of
severe infection once systemic immunosuppression was
discontinued.31,41 This apparent paradox prompted us to
assess long-term immune recovery after non-myeloabla-
tive conditioning. Several observations were made.
First and most importantly, while patients below 50
years of age at the time of HCT had evidence of thymic
recovery from day 100 to three years after HCT, thymic
recovery was much slower in patients aged 50 to 60 years,
and was virtually absent in patients over 60, even in those
without chronic GVHD. These results mirror those report-
ed by Hakim et al. in patients given autologous HCT
where the authors observed a significant thymic rebound
in approximately 80% of patients younger than 40 years,
45% of those aged 40 to 50 years, but in less than 15% of
those aged 50 years and older.42
Recovery of naïve CD4 T cells after HCT in current
patients somewhat mirrored recovery of thymic function
assessed by sjTREC levels. Specifically, recovery of naïve
T cells was observed by day 365 in patients below 50
years of age, but only at two years after HCT (and to a
lesser extent) in patients above 50-60 years of age. Further,
sjTREC levels correlated with those of CD4+CD45RA+ T
cells one year and over after HCT, and we observed a
strong correlation between sjTREC levels and naïve
CD4+CD45RA+CCR7+ T-cell and naïve CD8+ T-cell counts
two years after HCT. These observations are in agreement
with previous reports showing that new naïve T cells orig-
inate mainly from the thymic pathway after HCT.43,44
Given the slow or absent thymic recovery in patients
above 50 or 60 years, respectively,
immune recovery in those patients should have depended
mainly on peripheral expansion of mature T cells con-
tained in the graft. Consistent with this possibility, recov-
ery of CD8+ T cells occurred earlier than recovery of CD4+
T cells, and T-cell recovery was derived from memory
rather than naïve T cells.15 Interestingly, peripheral expan-
sion was sufficient to produce an efficient immune system
in the majority of patients without GVHD. Indeed, TCRB
repertoires were relatively complex both in patients with
low compared to high sjTREC levels, and incidences of
viral, bacterial and fungal infections were similar in
patients with low or high sjTREC levels. The risk of death
from infection was significantly higher in patients with
low sjTREC levels, although all but one patient who died
from infection had extensive severe chronic GVHD at the
time of death suggesting that GVHD or GVHD treatment
might also have played an important role in the risk of
mortality from infection in the current study. The observa-
tion that late immunity in older patients mainly depends
on mature T cells contained in the graft has important
implications since it suggests that long-term immune func-
tion after HCT might be affected by techniques of in vitro
or in vivo T-cell depletion of the graft in these patients.
Analysis of long-term immune recovery in older patients
given PBSC after alemtuzumab-based reduced-intensity
conditioning45 would be particularly interesting to confirm
this hypothesis.
Another observation of our study was the dramatic
impact of chronic GVHD on immune recovery.
Specifically, extensive chronic GVHD was significantly
associated with low sjTREC levels, as well as low counts
of CD4+ T cells, CD4+CD45RA+ (naïve) T cells, CD8+ T
cells and B cells one year and over after HCT, and was sig-
nificantly associated with lower counts of effector memo-
ry CD8+ T cells, effector memory RA+ CD8+ T cells, naïve
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Figure 4. CD4+ T-cell
(A), CD8+ T-cell (B) and
B-cell (C) phenotypes
two years after HCT in
patients with sjTREC
levels below (white
bars) or above (black
bars) median (1,000
sjTREC/μL) at that time
(n=33). CD4+ T-cell (D),
CD8+ T-cell (E) and B-
cell (F) subtype pheno-
types two years after
HCT in patients (white
bars) or (black bars)
under 57 years of age
or 57 years and over at
HCT. CD4+ T-cell (G),
CD8+ T-cell (H) and B-
cell (I) subtype pheno-
types two years after
HCT in patients without
(white bars) or with
(black bars) extensive
chronic GVHD at that
time. TCM, central
memory T cells; TEM,
effector memory T
cells; TEM RA+, TEM RA+
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B cell and memory B cells two years after HCT. The neg-
ative impact of chronic GVHD on immune recovery is
probably multi-factorial.46 First, the negative impact of
chronic GVHD on thymus architecture46 and function47-52
has been well demonstrated, and has been attributed to
direct donor T-cell alloreactivity towards recipient thy-
mus,53 and to a negative impact of immunosuppressive
drugs (and particularly of glucocorticosteroids) on the thy-
mus.54,55 Secondly, chronic GVHD has been shown to
impair peripheral expansion of mature T cells, and the
same is obviously true for immunosuppressive drugs
given in the treatment of patients with chronic GVHD.
Thirdly, chronic GVHD has been associated with reduced
B-cell lymphopoiesis perhaps because of B-cell inhibitory
cytokines produced by activated T cells in chronic GVHD
patients or because of GVHD treatments.56
In summary, our data suggest that thymic neo-genera-
tion of T cells occurs from day 100 onwards in patients
under 60 years of age. In contrast, the levels of sjTREC
remain low for patients over 60 who depended nearly
exclusively on peripheral expansion of mature donor T
cells contained in the graft to reconstitute their T-cell com-
partment. This suggests that long-term immune function
after HCT might be negatively impacted by techniques of
in vitro or in vivo T-cell depletion of the graft in older
patients given allogeneic HCT.
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